Last reviewed 2026-04-22 · How we verify

anti-CD25 rhMAb

This recombinant humanized monoclonal antibody binds to CD25 (IL-2 receptor alpha chain) on activated T cells, blocking interleukin-2 signaling and suppressing T cell proliferation and activation.

This recombinant humanized monoclonal antibody binds to CD25 (IL-2 receptor alpha chain) on activated T cells, blocking interleukin-2 signaling and suppressing T cell proliferation and activation. Used for Autoimmune and inflammatory disorders (specific approved indications not definitively documented in public sources).

At a glance

Mechanism of action

CD25 is highly expressed on activated T lymphocytes and regulatory T cells. By targeting CD25, this antibody prevents IL-2-mediated T cell expansion and can modulate immune responses. This mechanism is used therapeutically in autoimmune and inflammatory conditions where T cell activation drives pathology, and has also been explored in transplantation to prevent rejection.

Approved indications

• Autoimmune and inflammatory disorders (specific approved indications not definitively documented in public sources)

Common side effects

• Infection
• Immunosuppression-related adverse events

Key clinical trials

• Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model (PHASE2)
• Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• anti-CD25 rhMAb CI brief — competitive landscape report
• anti-CD25 rhMAb updates RSS · CI watch RSS
• Peking University People's Hospital portfolio CI